← 返回

成熟三级淋巴结构与头颈部鳞状细胞癌中 HPV 状态及抗 PD-1 联合化疗免疫治疗反应相关

英文原题:Mature tertiary lymphoid structures linked to HPV status and anti-PD-1 based chemoimmunotherapy response in head and neck squamous cell carcinoma.

查看英文原题

Mature tertiary lymphoid structures linked to HPV status and anti-PD-1 based chemoimmunotherapy response in head and neck squamous cell carcinoma.

PubMed 2025/07/07(内容时间) Oncoimmunology Q1 · IF 6.2(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

成熟的三级淋巴结构(TLSs)是与多种癌症中免疫检查点阻断(ICB)应答相关的免疫聚集体,但其在头颈部鳞状细胞癌(HNSCC)化疗免疫治疗应答中的作用仍不清楚。通过分析TCGA-HNSC转录组数据和病理切片,我们鉴定出一个富含TLSs的免疫亚型,主要见于HPV阳性肿瘤,并与良好的免疫治疗应答相关。单细胞和空间转录组学进一步揭示了不同的TLS组成,成熟TLSs富含生发中心B细胞、滤泡辅助性T细胞和驻留记忆CD8 T细胞,而未成熟TLSs则包含FCRL4+ B细胞和外周辅助性T细胞。多重免疫组化、流式细胞术和ELISA验证了这些发现。值得注意的是,新辅助化疗免疫治疗促进了成熟TLS的形成。这些结果表明,TLS成熟度与HPV状态及基于抗PD-1的化疗免疫治疗应答相关,为HNSCC的潜在治疗策略提供了见解。

展开英文摘要原文

Mature tertiary lymphoid structures (TLSs) are immune aggregates associated with immune checkpoint blockade (ICB) responses in various cancers, yet their role in chemoimmunotherapy response in head and neck squamous cell carcinoma (HNSCC) remains unclear. By analyzing TCGA-HNSC transcriptomic data and pathology slides, we identified an immune subtype enriched in TLSs, predominantly in HPV-positive tumors, which correlated with favorable immunotherapy response.

Single-cell and spatial transcriptomics further revealed distinct TLS compositions, with mature TLSs enriched in germinal center B cells, follicular helper T cells, and resident memory CD8 T cells, while immature TLSs contained FCRL4+ B cells and peripheral helper T cells. Multispectral immunohistochemistry, flow cytometry, and ELISA validated these findings.

Notably, neoadjuvant chemoimmunotherapy promoted mature TLS formation. These results suggest that TLS maturity correlates with HPV status and response to anti-PD-1-based chemoimmunotherapy, providing insights for potential therapeutic strategies in HNSCC.

论文信息

作者
Zhang L、Ren S、Lan T、Marco V、Liu N、Wei B、Chen Y、Wu J
单位
Department of Oral and Maxillofacial Surgery, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China.China
期刊
Oncoimmunology2025 Dec
原文标识
PubMed 40621740 · DOI 10.1080/2162402X.2025.2528109